National Bank of Canada
RNAC icon

National Bank of Canada’s Cartesian Therapeutics RNAC Stock Holding History

National Bank of Canada’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40
Closed -$415 – 3164
2025
Q2 		$415 Hold
40
– – ﹤0.01% 2783
2025
Q1 		$524 Hold
40
– – ﹤0.01% 2641
2024
Q4 		$716 Buy
+40
New +$810 ﹤0.01% 2686
2024
Q3 		– Sell
-40
Closed -$970 – 2996
2024
Q2 		$970 Buy
+40
New +$955 ﹤0.01% 2513
2024
Q1 		– Sell
-45
Closed -$872 – 2892
2023
Q4 		$872 Hold
45
– – ﹤0.01% 2550
2023
Q3 		$1.39K Hold
45
– – ﹤0.01% 2552
2023
Q2 		$1.5K Hold
45
– – ﹤0.01% 2506
2023
Q1 		$1.84K Buy
+45
New +$2.12K ﹤0.01% 2449

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

National Bank of Canada's RNAC Position: Q3 2025 in Review

National Bank of Canada sold out of Cartesian Therapeutics (RNAC) in Q3 2025, closing a stake of 40 shares — an estimated $415 sold.

National Bank of Canada first reported a position in RNAC in Q1 2023 and held it in 8 quarters. The position peaked at $1.84K in Q1 2023. 68 funds tracked by Wall St. Rank hold RNAC as of Q3 2025.

  • National Bank of Canada reported no remaining Cartesian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • National Bank of Canada sold 40 Cartesian Therapeutics shares in Q3 2025, an estimated $415.
  • National Bank of Canada first reported a position in Cartesian Therapeutics in Q1 2023 and held it in 8 quarters.
  • National Bank of Canada's Cartesian Therapeutics position peaked at $1.84K in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2025.

Based on National Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.